Pomerantz LLP’s Post

Evgen has announced the acquisition of Chronos Therapeutics Limited, a specialist company in central nervous system (CNS) treatments. The acquisition consideration comprises an initial payment of £899,481 payable in Ordinary Shares at a price of 1.44 pence per Ordinary Share, potentially increasing to £3.4 million subject to the achievement of certain milestones.   In addition, Evgen has conditionally raised £0.85 million (before expenses) via a Placing and Subscription and will seek authority to raise further funds on the same terms.   To provide Shareholders who have not taken part in the Placing or the Subscription with an opportunity to participate in the Fundraising, the Company is offering up to 100,000,000 Retail Offer Shares at the Issue Price, via the Bookbuild Platform, to raise up to an additional £1.0 million (before expenses), by way of the Retail Offer.   The Company has also proposed a change of name to TheraCryf plc, with a new TIDM of TCF. The change of name will become effective and will be announced separately post-Admission.   Details of the acquisition, Placing and Subscription, and Retail Offer can be found on the Investor Relations page of the website here: https://bit.ly/3vjCLJV   #EvgenPharma #Chronos #Acquisition #RetailInvestor #TheraCryf

BillionToOne, a pioneering molecular diagnostics company, has announced a successful Series D funding round, raising $130 million. The oversubscribed round was led by Premji Invest, with substantial contributions from new investor Neuberger Berman and existing investors such as Adam Street Partners, Baillie Gifford, Hummingbird Ventures, Civilization Ventures, Libertus Capital, and Fifty Years. This significant influx of capital will be utilized to expand and scale BillionToOne’s prenatal screening and oncology diagnostics businesses. BillionToOne’s cutting-edge technology, Quantitative Counting Templates™ (QCTs™), enables the precise counting of DNA molecules at the single base-pair level. This innovation has allowed the company to develop unique and differentiated tests that push the boundaries of molecular diagnostics. To date, over half a million patients have benefited from BillionToOne’s tests, and the company has seen remarkable growth, achieving an annual recurring revenue of $125 million in just four years. Read more: https://lnkd.in/dB74aWEv

Karyopharm Shareholders: ENOUGH IS ENOUGH! Richard Paulson has not responded to Uncle Rolli Greer and I. We set clear expectations and set lots of ideas for free on how to fix KPTI. The response? Silence. Richard is not a leader - he does not understand Multiple Myeloma or Myelofibrosis Neoplasms like Uncle Rolli, Jennifer M. Little-Vito, and I do. Folks: this is a shame. Barry Greene is a JOKE of a director. Fire him! HOW DO YOU SIT ON THE BOARDS OF TWO COMPANIES AND BE A CEO? THIS IS WHY Karyopharm Therapeutics Inc., Sage Therapeutics, and other Boston Biotech Advisors, LLC companies FAIL, Jefferies! Garen Bohlin is a JOKE TOO. WHO DO THEY THINK THEY ARE? HOW DO THEY STILL HAVE THEIR JOBS? THEY ARE ROBBING SHAREHOLDERS BLIND. All three of them are worth fortunes compared to you and I. They do not buy shares of KPTI like Uncle Rolli and I have. They do not have plans to fix KPTI - they are corrupt, got sued by Amgen for violating non-competes, and continue to rob shareholders blind. This is all public information - if you look at Google News or Cafepharma, Inc! WAKE UP PEOPLE! Come join the party on Stocktwits and Stocktwits India 🇮🇳! 1) Fire CEO Richard Paulson 2) Fire Barry Greene from the board 3) Remove Garen Bohlin too. They do NOTHING but rob shareholders like us blind! This is a God Damn JOKE! Patients are waiting, gentlemen! Tick Tock! 😎 ~Jeff Conroy Global HC Analytics LLC Founder & Oncology Forecasting Expert Email: jconroy@theghca.com P.S. Glioblastoma Foundation patients are waiting, boys! XPOVIO® (selinexor) HCP might help Cure Glioblastoma for children with who suffer like the Pediatric Cancer Research Foundation knows. TICK TOCK! 🏗 Every single KPTI shareholder is sick and tired of this piss poor management. Shareholders need to know! Our lawyers and fellow former employees are too. We can fix KaryoPharm Therapeutics, stop the egregious annual 9.9% price increases of XPOVIO that rob 2017 Medicare Part D Plans BLIND, and save the company once and for all. Employees asked me to. Here we go. 😘 https://lnkd.in/erwfgUYB

Reposting to highlight the potential of disruptive innovation in cellular therapies! Companies like Celleres and Ori Biotech are making significant strides, but for cellular therapies to rapidly advance and achieve scale, we need to apply this disruptive thinking across the entire value chain. This means embracing innovation at the treatment centers, within biopharma organizations, and with third-party support organizations. I’m curious to hear from my network: which areas do you think would benefit most from these disruptive approaches? Let’s discuss how we can drive this industry forward together. #CellTherapy #Biotech #Innovation #Healthcare #DisruptiveInnovation #Pharma #Biopharma #HealthcareInnovation #FutureOfMedicine

Biotech companies are turning tide when it comes to financing and especially companies that acquire supportive early clinical data while investors are still mostly on the side when it comes to those with preclinical package. One of the biotechs at the forefront of AI-guided development, #BioXcel Therapeutics, showcases successful navigation of the financing while reaching late stage clinical development. Today it received Fast Track designation by FDA for BXCL701, oral innate immune activator designed to initiate inflammation in the tumor microenvironment for combination with a checkpoint inhibitor for the treatment of patients with metastatic small cell neuroendocrine prostate cancer (SCNC) with progression on chemotherapy and no evidence of microsatellite instability. It has shown positive clinical proof of concept in both SCNC and adenocarcinoma with positive survival results from Phase 2 trial. https://lnkd.in/eMyJsR4s #Biotech #oncology #clinicaloncology #prostatecancer #clinical development strategy https://lnkd.in/eEb3Np2p

Boundless Bio, a startup in the clinic with two small molecules for cancer, priced its $100 million IPO Wednesday night and will start trading as $BOLD on Thursday morning. The Nasdaq debut comes 10 months after it disclosed a Series C of the same size. Its bell ringing in Times Square will likely be followed by a fellow clinical-stage San Diego biotech, as J&J-partnered Contineum Therapeutics has also outlined plans for an IPO. Boundless sought an IPO as early as last fall, with an SEC filing from Sept. 1 indicating it could seek a 2023 listing. “We’re thinking about this as a fourth revolution in cancer therapies,” CEO Zachary Hornby told Endpoints News when the company unveiled in 2019. Chemotherapy, targeted medicines and immunotherapy were the first three, by his telling. Prolific life sciences investor and incubator ARCH Venture Partners formed the biotech a little over five years ago to go after extrachromosomal DNA. #biotech #bold #nasdaq #ipo #initialpublicoffering #drugdevelopment #cancerresearch

Making clinical trials more accessible means better outcomes for patients and a faster time to market for life saving drugs. McKesson Ventures partner, Carrie (Hurwitz) Williams, will share her perspective on democratizing access to clinical trials at the upcoming Oncology Venture, Innovation, and Partnering summit. Learn more about how McKesson Ventures is investing in innovation: https://lnkd.in/g2iwwq6f

Are you curious about the future of community oncology practices amidst increasing hospital consolidation? Read this insightful article that provides a deep dive into the challenges and strategies being implemented to maintain independence and quality care. Learn from experts like Jeff Patton, MD, and explore the rise of management services organizations as a potential solution for community practices. #Oncology #HealthcareTrends #CommunityPractices #HospitalConsolidation

We are delighted to announce the successful closing of an oversubscribed Series D financing, raising $181.4M to develop a deep pipeline of CLDN1 targeted medicines for solid tumors. The funding was supported by a syndicate of top-tier biotech investors including OrbiMed as lead and Novo Holdings and JEITO as co-leads as well as substantial contributions from Frazier Life Sciences, Longitude Capital, RA Capital Management, and Catalio Capital Management. This financing is a testament to the transformational potential of CLDN1 targeted medicine in oncology, in particular our first-in-class antibody-drug conjugates (#ADCs) ALE.P02 and ALE.P03. We’re excited to start Phase 1/2 clinical trials for both programs in 2025. Read the full press release: https://lnkd.in/eVSGPG5G We extend our deepest gratitude to our investors for their trust and support. Together we are making a difference 🌍💙 #AlentisTherapeutics #Biotech #Funding #Healthcare #LifeSciences #ADC #CLDN1 #Claudin

this… I remember when as a researcher writing grants always had to have some “magic bullet, this will cure disease XYZ” spin in order to get funding, despite being clearly fundamental research. Similarly, when investors push technology developers into therapy developments (or company leadership willingly moves in that direction because of market murmurs and dollar signs) while core competencies are not aligned, focus gets lost and resources diluted. Back of the envelop assumptions: Therapy development is expensive and fails 90% of the time - given that tech development has a success rate of about 30%, ergo a failure rate of about 70% in itself, the compounded risk of two assets depending on each other is quite significant. (opinions expressed are my own)